Is drug allergy less prevalent than previously assumed? A 5-year analysis

British Journal of Dermatology

Volumn 166, Issue 1, 2012, Pages 107-114

  Heinzerling, L M ^a,b   Tomsitz, D ^a   Anliker, M D ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CEFAMANDOLE NAFATE; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CONTRAST MEDIUM; DALTEPARIN; DICLOFENAC; GLUCOCORTICOID; IBUPROFEN; IMIPENEM; LOCAL ANESTHETIC AGENT; METHYLPHENIDATE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PARACETAMOL; PHENOBARBITAL; PROPRANOLOL; PROTON PUMP INHIBITOR; TRIMIPRAMINE; UNINDEXED DRUG;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRESS SYNDROME; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACUTANEOUS TEST; LYMPHOCYTE TRANSFORMATION TEST; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; PATCH TEST; PRESCHOOL CHILD; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; SCHOOL CHILD; SKIN MANIFESTATION; SKIN TEST; STEVENS JOHNSON SYNDROME; TERTIARY HEALTH CARE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS; VESICULAR RASH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SKIN TESTS; SWITZERLAND; YOUNG ADULT;

EID: 84555196806     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10623.x     Document Type: Article

References (46)

1. Jick H, Miettinen OS, Shapiro S, et al. Comprehensive drug surveillance. JAMA 1970; 213: 1455-60.
2. Bigby M, Jick S, Jick H, Arndt K,. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975-1982. JAMA 1986; 256: 3358-63. (Pubitemid 17201796)
3. Friedmann PS, Pickard C, Ardern-Jones M, Bircher AJ,. Drug-induced exanthemata: a source of clinical and intellectual confusion. Eur J Dermatol 2010; 20: 255-9.
4. Ramdial PK, Naidoo DK,. Drug-induced cutaneous pathology. J Clin Pathol 2009; 62: 493-504.
5. Pichler WJ,. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-93.
6. Schnyder B, Pichler WJ,. Mechanisms of drug-induced allergy. Mayo Clin Proc 2009; 84: 268-72.
7. Pichler WJ, ed. Drug hypersensitivity reactions: classifications and relationships to T-cell activation. In: Drug Hypersensitivity. Basel: Karger, 2007: 168-89.
8. Gomes ER, Demoly P,. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309-16. (Pubitemid 41017644)
9. Gerson D, Sriganeshan V, Alexis JB,. Cutaneous drug eruptions: a 5-year experience. J Am Acad Dermatol 2008; 59: 995-9.
10. Hernandez-Salazar A, Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37: 899-902. (Pubitemid 44333152)
11. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018-22. (Pubitemid 37541988)
12. Ding WY, Lee CK, Choon SE,. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010; 49: 834-41.
13. Huang HY, Luo XQ, Chan LS, et al. Cutaneous adverse drug reactions in a hospital-based Chinese population. Clin Exp Dermatol 2011; 36: 135-41.
14. Lee HY, Tay LK, Thirumoorthy T, Pang SM,. Cutaneous adverse drug reactions in hospitalised patients. Singapore Med J 2010; 51: 767-74.
15. Pudukadan D, Thappa DM,. Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India. Indian J Dermatol Venereol Leprol 2004; 70: 20-4. (Pubitemid 39217020)
16. Sehgal S, Balachandran C, Shenoi SD,. Clinical study of cutaneous drug reactions in 80 patients. Indian J Dermatol Venereol Leprol 2003; 69: 6-7. (Pubitemid 44943133)
17. Hunziker T, Kunzi UP, Braunschweig S, et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-93. (Pubitemid 27244150)
18. Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2: 1056-8. (Pubitemid 16206749)
19. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45. (Pubitemid 12149145)
20. Nebeker JR, Barach P, Samore MH,. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140: 795-801. (Pubitemid 38623529)
21. Torres MJ, Mayorga C, Blanca M,. Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J Investig Allergol Clin Immunol 2009; 19: 80-90.
22. Borch JE, Andersen KE, Bindslev-Jensen C,. Cutaneous adverse drug reactions seen at a university hospital department of dermatology. Acta Derm Venereol 2006; 86: 523-7. (Pubitemid 44950746)
23. Borch JE, Andersen KE, Bindslev-Jensen C,. The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital. Acta Derm Venereol 2006; 86: 518-22. (Pubitemid 44950745)
24. Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51. (Pubitemid 34146185)
25. Seitz CS, Brocker EB, Trautmann A,. Allergy diagnostic testing in clindamycin-induced skin reactions. Int Arch Allergy Immunol 2009; 149: 246-50.
26. Seitz CS, Brocker EB, Trautmann A,. Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clin Exp Allergy 2009; 39: 1738-45.
27. Schubert B, Grosse Perdekamp MT, Pfeuffer P, et al. Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol 2005; 15: 164-7. (Pubitemid 40733422)
28. Surtees SJ, Stockton MG, Gietzen TW,. Allergy to penicillin: fable or fact? BMJ 1991; 302: 1051-2.
29. Mockenhaupt M,. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7: 142-60.
30. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88: 60-8.
31. Osawa J, Naito S, Aihara M, et al. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 1990; 17: 235-9. (Pubitemid 20191485)
32. Bruynzeel DP, Maibach HI,. Patch testing in systemic drug eruptions. Clin Dermatol 1997; 15: 479-84. (Pubitemid 27315166)
33. Calkin JM, Maibach HI,. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993; 29: 223-33. (Pubitemid 23346379)
34. Romano A, Quaratino D, Di Fonso M, et al. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol 1999; 103: 1186-90. (Pubitemid 29343088)
35. Barbaud A, Goncalo M, Bruynzeel D, Bircher A,. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321-8. (Pubitemid 34056345)
36. Brockow K, Romano A, Aberer W, et al.; European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. Skin testing in patients with hypersensitivity reactions to iodinated contrast media-a European multicenter study. Allergy 2009; 64: 234-41.
37. Pichler WJ, Tilch J,. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-20. (Pubitemid 39005820)
38. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854-63. (Pubitemid 37046682)
39. Nyfeler B, Pichler WJ,. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27: 175-81. (Pubitemid 27085418)
40. Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158-67. (Pubitemid 30068294)
41. Thong BY, Leong KP, Tang CY, Chng HH,. Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003; 90: 342-7.
42. Classen DC, Pestotnik SL, Evans RS, Burke JP,. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847-51.
43. Messaad D, Sahla H, Benahmed S, et al. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004; 140: 1001-6.
44. Romano A, Viola M, Gaeta F, et al. Patch testing in non-immediate drug eruptions. Allergy Asthma Clin Immunol 2008; 4: 66-74. (Pubitemid 351880900)
45. Roujeau JC,. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9.
46. Raksha MP, Marfatia YS,. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol 2008; 74: 80.